21st week of 2011 patent applcation highlights part 49 |
Patent application number | Title | Published |
20110124604 | PHOSPHOLIPID RECEPTORS AS TARGETS FOR ENHANCING DRUG PERMEABILITY TO SELECTED TISSUES - A method for enhancing drug delivery to the brain in neurological disorders using lysophosphatidic acid (LPA) and sphingosine I phosphate (S1P) is herein described. Specifically, the permeability properties of LPA and S1P allow for a highly controlled and transient disruption of blood-brain barrier permeability. Thus these phospholipids can be used for delivering a wide variety of therapeutic, prophylactic or diagnostic agents to the brain. | 2011-05-26 |
20110124605 | Use of an S1P Receptor Agonist - The present invention relates to new uses of S1P receptor modulator or agonist such as fingolimod, for reducing or delaying the progression of cerebral atrophy. | 2011-05-26 |
20110124606 | SENSE-IMPROVING AGENT - Disclosed are: a sense-improving agent which comprises, as an active ingredient, a phospholipid or a sphingosine-containing phospholipid and/or a derivative thereof, particularly a sphingomyelin, and which has an effect of improving the dulling of senses at a periphery when ingested orally or directly applied to the skin; and a sense-improving food, beverage, feed or cosmetic comprising the sense-improving agent. The phospholipid to be used may be a chemically synthesized phospholipid or a naturally occurring phospholipid, preferably a phospholipid derived from an edible material such as soybean and egg yolk, particularly preferably a phospholipid derived from milk. | 2011-05-26 |
20110124607 | COMPOSITION FOR REGULATION CELLULAR SENESCENCE COMPRISING LYSOPHOSPHATIDIC ACID AND INHIBITOR OF ADENYLYL CYCLASE AS ACTIVE INGREDIENTS - The present invention relates to the molecular mechanism inducing cell proliferation in aged human fibroblasts by inhibiting AMPK using LPA and AC inhibitor. Particularly, the present invention relates to a composition comprising LPA and ACI as active ingredients and the invention proves with the said composition that LPA and ACI regulate different phosphorylation of AMPKα and thus inactivate p53 and induce senescent cell proliferation. This results support the fact that AMPK signal transduction plays an important role in cell proliferation of senescent cells. | 2011-05-26 |
20110124608 | USE OF 25-HYDROXY VITAMIN D3 TO INCREASE MUSCLE MASS IN MAMMALS - Myogenesis in mammals can be promoted by a prenatal administration of 25-hydroxy vitamin D3 (25-OH D3). The 25-OH D3 can be administered to the pregnant mother, and the amount of muscle tissue in the offspring is increased relative to control mammals. Optimally, the 25-OH D3 supplements the diet continuously postnatally. | 2011-05-26 |
20110124609 | Method of Preventing Type I Diabetes - The invention relates to novel methods of using 2α-methyl-19-nor-20(S)-1α,25-dihydroxyvitamin D | 2011-05-26 |
20110124610 | METHOD FOR INCREASING BONE DENSITY AND/OR REDUCING ANY OSTEOCHONDRAL DEFECTS IN AN ANIMAL AND A COMPOSITION INCLUDING VITAMIN K - There is disclosed herein a method of increasing bone density, maintaining bone density and/or inhibiting loss of bone density and/or reducing osteochondral defects in an animal comprising administering to an animal an effective amount of a composition containing: vitamin K1, vitamin K2 or a mixture of vitamin K1 and vitamin K2, together with a physiologically acceptable carrier, incipient and/or diluent. Various compositions including vitamin K are also disclosed. | 2011-05-26 |
20110124611 | METHODS OF HORMONAL TREATMENT UTILIZING CONTRACEPTIVE REGIMENS WITH CONTINUOUS ESTROGEN ADMINISTRATION - The present invention provides contraceptive regimens in which a female is administered a combined dosage form of estrogen and progestin followed by a period of administration of estrogen. The disclosed contraceptive regimens can be administered to a female as a method of providing non-contraceptive benefits. | 2011-05-26 |
20110124612 | MULTI-PHASE CONTRACEPTIVE PREPARATION BASED ON A NATURAL ESTROGEN - The multiphase preparation having higher contraceptive safety and reduced side effects is based on a combination of a natural oestrogen with dienogest or drospirenon. The multiphase prepration is characterized by a first phase consisting of 2 daily dose dose units of 3 mg of oestradiol valerate, a second phase consisting of 2 groups of daily dose units, wherein a first group is formed by 5 daily dose units each containing a combination of 2 mg of oestradiol valerate and at least two or three times an ovulation-inhibitory dose of dienogest or drospirenon and a second group is formed by 17 daily dose units each containing a combination of 2 mg of oestradiol valerate and at least three or four times the ovulation-inhibitory dose of dienogest or drospirenon, a third phase consisting of 2 daily dose units of 1 mg of oestradiol valerate, and a further phase consisting of 2 daily dose units of pharmaceutically acceptable placebo. | 2011-05-26 |
20110124613 | Novel Combination of Compounds to be Used in the Treatment of Airway Diseases, Especially Chronic Obstructive Pulmonary Disease (COPD) and Asthma - The present invention provides a pharmaceutical product comprising, in combination of, (a) a (therapeutically effective) dose of a first active ingredient, which is a compound of formula (I) or a pharmaceutically acceptable salt thereof; and (b) a (therapeutically effective) dose of a second active ingredient, which is a glucocorticoid receptor agonist; and optionally, (c) a (therapeutically effective) dose of a third active ingredient, which is a β | 2011-05-26 |
20110124614 | Methods And Compositions For The Treatment of Autoimmune Disorders - Methods and compositions are provided which confer protection against autoimmune diseases without triggering intracellular estrogen receptors. Such methods and compositions limit the side effects of steroids while providing the benefits conferred by such medications through the activation of membrane estrogen receptors. | 2011-05-26 |
20110124615 | USE OF FUMARIC ACID DERIVATIVES FOR TREATING CARDIAC INSUFFICIENCY, AND ASTHMA - According to a first aspect the invention relates to the use of fumaric acid derivatives selected from the group consisting of dialkyl fumarates, monoalkyl hydrogen fumarates, fumaric acid monoalkyl ester salts, fumaric acid monoamides, monoamido fumaric acid salts, fumaric acid diamides, monoalkyl monoamido fumarates, carbocyclic and oxacarbocyclic oligomers of these compounds and mixtures thereof for preparing a drug for the treatment or prevention of cardiac insufficiency, in particular left ventricular insufficiency, myocardial infarction and angina pectoris. | 2011-05-26 |
20110124616 | METHOD FOR TREATING RETINAL CONDITIONS USING AN INTRAOCULAR TAMPONADE - A composition includes at least one fatty acid glycerol ester for use during or after a vitrectomy procedure, the composition being bioresorbable, being injectable in the vitreous cavity, having a density below 1, more preferably between 0.90 and 1, or a density above 1, more preferably between 1 and 1.5; having a surface tension of less than 50 dynes/cm more preferably ranging from 20 and 30 dynes/cm, being not susceptible to emulsify into droplets when injected; method for treating a retinal disorder involving the use of the composition. | 2011-05-26 |
20110124617 | Combination Therapy for BreastCancer Comprising an Antiestrogenic Agent - This invention relates to combination therapies for the treatment of breast cancer comprising administering to a subject in need thereof a compound of Formula I or a pharmaceutically acceptable salt thereof and an anti-estrogenic agent (e.g., an aromatase inhibitor, a SERM that is not the SERM of Formula I, a GNRH agonist, a GNRH antagonist, or an estrogen receptor downregulator) and to compositions (e.g., pharmaceutical compositions) comprising a compound of Formula I or a pharmaceutically acceptable salt thereof and an anti-estrogenic agent. This invention also relates to a method of treating the side effects (e.g., vasomotor disturbances, osteoporosis and musculoskeletal complaints) associated with anti-estrogen therapy in a subject treated with one or more anti-estrogenic agents (e.g., an aromatase inhibitor, a SERM that is not the SERM of Formula I, a GNRH agonist, a GNRH antagonist or an estrogen receptor downregulator). The method comprises administering to the subject an effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof. | 2011-05-26 |
20110124618 | SUBSTITUTED (PYRAZOLYLCARBONYL)IMIDAZOLIDINONES AND THEIR USE - The present invention relates to novel substituted (pyrazolylcarbonyl)imidazolidinones, methods for their preparation, their use for the treatment and/or prophylaxis of diseases, as well as their use for the manufacture of medicaments for the treatment and/or prophylaxis of diseases, especially of retroviral diseases, in humans and/or animals. | 2011-05-26 |
20110124619 | Pyrimidine Sulphonamide Derivatives as Chemokine Receptor Modulators - A compound of formula (I), or a pharmaceutically acceptable salt, solvate or in vivo hydrolysable ester thereof and pharmaceutical compositions comprising these, all for use in the treatment of chemokine mediated diseases and disorders. | 2011-05-26 |
20110124620 | SPHINGOSINE 1 PHOSPHATE RECEPTOR MODUATORS AND THEIR USE TO TREAT MUSCLE INFLAMMATION - The use of an S1P receptor modulator of the formula (Ia) or (Ib) wherein the meaning of the different residues is that indicated in claim | 2011-05-26 |
20110124621 | BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS - A compound of formula I | 2011-05-26 |
20110124622 | ISOINDOLONES DERIVATIVES AS MEK KINASE INHIBITORS AND METHODS OF USE - The invention relates to isoindolones of formula, (I) with anti-cancer and/or anti-inflammatory activity and more specifically with MEK kinase inhibitory activity. The invention provides compositions and methods useful for inhibiting abnormal cell growth, treating a hyperproliferative disorder, or treating an inflammatory disease in a mammal. The invention also relates to methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions. | 2011-05-26 |
20110124623 | PYRROLOTRIAZINE KINASE INHIBITORS - The invention provides compounds of formula I | 2011-05-26 |
20110124624 | 5-PHENYL-4-METHYL-THIAZOL-2-YL-AMINE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL 3 KINASE ENZYMES (PI3) FOR THE TREATMENT OF INFLAMMATORY DISEASES - Compounds of Formula I: | 2011-05-26 |
20110124625 | Modulators of Cellular Adhesion - The present invention provides compounds having formula (I): | 2011-05-26 |
20110124626 | BENZAZEPINE DERIVATIVES AND THEIR USE AS HISTAMINE H3 ANTAGONISTS - A compound having the formula (1) wherein: R1 is a group selected from C | 2011-05-26 |
20110124627 | MODULATORS OF TOLL-LIKE RECEPTORS - The present application includes novel modulators of TLRs, compositions containing such compounds, therapeutic methods that include the administration of such compounds. | 2011-05-26 |
20110124628 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES - Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein. | 2011-05-26 |
20110124629 | Crystalline Forms of a Pharmaceutical Compound - Described are crystalline forms of the pharmaceutical compound “[9S-(9α,10β,12α)]-5,16-Bis[(ethylthio)methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-9,12-epoxy-1H-diindolo[1,2,3 -fg:3′,2′,1′-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid methyl ester”, as well as methods for their use and preparation. | 2011-05-26 |
20110124630 | STEMONAMIDE SYNTHESIS INTERMEDIATE AND PHARMACEUTICAL COMPOSITION FOR PREVENTION AND/OR TREATMENT OF CANCER - An objective of the invention is to provide a compound effective for prevention and/or treatment of cancer. The invention relates to a compound according to by formula I, or a salt, solvate or physiologically functional derivative thereof, and a composition for prevention and/or treatment of cancer comprising the same as an active ingredient: | 2011-05-26 |
20110124631 | TREATMENT OF COGNITIVE DISORDERS WITH CERTAIN ALPHA-7 NICOTINIC ACID RECEPTORS IN COMBINATION WITH ACETYLCHOLINESTERASE INHIBITORS - A method for improving cognition comprising administering to a patient (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide or a pharmaceutically acceptable salt thereof and an acetylcholinesterase inhibitor is described together with related compositions. | 2011-05-26 |
20110124632 | IMIDAZOPYRIDINES AS A NOVEL SCAFFOLD FOR MULTI-TARGETED KINASE INHIBITION - Compounds that inhibit protein kinases, compositions containing the compounds and methods of treating diseases using the compounds are disclosed. | 2011-05-26 |
20110124633 | Heterocyclic Compounds, Methods of Making Them and Their Use in Therapy - In part, the present invention is directed to antibacterial compounds. | 2011-05-26 |
20110124634 | BIOACTIVE COMPOUNDS FOR TREATMENT OF CANCER AND NEURODEGENERATIVE DISEASES - The invention provides bioactive compounds for the treatment of various malconditions such as cancer and neurodegenerative diseases including Alzheimer's disease. The chemical compounds as disclosed herein are found to show bioactivity in bioassays related to these conditions. Pharmaceutical compositions, combinations and methods of synthesis are provided, as are methods of using the compound, compositions and combinations in the treatment of the diseases. | 2011-05-26 |
20110124635 | Cyclic Inhibitors Of 11Beta-Hydroxysteroid Dehydrogenase 1 - This invention relates to novel compounds of the Formula (I), (II), 1u | 2011-05-26 |
20110124636 | 2-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS - The invention relates to novel 2-aza-bicyclo[3.1.0]hexane derivatives of Formula (I) wherein A, B, n and R | 2011-05-26 |
20110124637 | BENZIMIDAZOLES AND RELATED ANALOGS AS SIRTUIN MODULATORS - Provided herein are sirtuin-modulating compounds of formula (II). The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders relating to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent. | 2011-05-26 |
20110124638 | Pyrido-, Pyrazo- and Pyrimido-Pyrimidine Derivatives as mTOR Inhibitors - There is provided a compound of formula I: | 2011-05-26 |
20110124639 | 3 BETA-HYDROXYSTEROID DEHYDROGENASE INHIBITORS - The present invention relates to methods of treating a patient infected by | 2011-05-26 |
20110124640 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS KINASE MODULATORS - Compounds having the formula (I), and enantiomers, and diastereomers, pharmaceutically-acceptable salts, thereof, are useful as kinase modulators, including Btk modulation, wherein R | 2011-05-26 |
20110124641 | BENZOTHIAZOLE KINASE INHIBITORS AND METHODS OF USE - The present invention provides chemical entities or compounds and pharmaceutical compositions thereof that are capable of modulating lipid kinases such PI3 kinases, tryosine kinases and protein kinases such as mTOR. Also provided in the present invention are methods of using these compositions to modulate these kinases especially for therapeutic applications. | 2011-05-26 |
20110124642 | POTASSIUM CHANNEL MODULATORS - Disclosed herein are KCNQ potassium channels modulators of formula (I) | 2011-05-26 |
20110124643 | PYRIDINOPYRIDINONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF - The present invention relates to pyridopyridone derivatives of formula (I): | 2011-05-26 |
20110124644 | METHODS OF DIAGNOSING AND CHARACTERIZING CANNABINOID SIGNALING IN CROHN'S DISEASE - Diagnosis of Crohn's Disease by determining the presence or absence of variants at the CNR2 (cannabinoid) genetic locus and serological markers is disclosed Methods of diagnosing a Crohn's Disease sub-type by determining the presence or absence of one or more risk variants at the CNR2 5 locus and the presence or absence of ASCA, OmpC, 12 and/or anti-Cbir1 antibodies are included | 2011-05-26 |
20110124645 | FLUOROALKOXY-SUBSTITUTED 1,3-DIHYDRO-ISOINDOLYL COMPOUNDS AND THEIR PHARMACEUTICAL USES - The invention encompasses novel compounds, pharmaceutically acceptable salts, hydrates, solvates, clathrates, enantiomers, diastereomers, racemates, or mixtures of stereoisomers thereof, pharmaceutical compositions of these compounds, and methods of using these compounds and compositions in mammals for treatment or prevention of diseases associated with PDE4. | 2011-05-26 |
20110124646 | Novel cyclic compound having pyrimidinylalkylthio group - A method of treating a disease associated with angiogenesis by administering a therapeutically effective amount of a compound represented by the formula (1) or a salt thereof | 2011-05-26 |
20110124647 | INSECTICIDAL DERIVATIVES OF SUBSTITUTED BENZYLAMINES - The present invention relates to novel derivatives of substituted benzylamines, to processes for their preparation and to their use for controlling animal pests, especially arthropods, in particular insects. | 2011-05-26 |
20110124648 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES - The present invention discloses novel compounds of Formula I, or pharmaceutically acceptable salts thereof, which have glucagon receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I as well as methods of using them to treat diabetic and other glucagon related metabolic disorders, and the like. | 2011-05-26 |
20110124649 | INHIBITORS OF HUMAN METHIONINE AMINOPEPTIDASE 1 AND METHODS OF TREATING DISORDERS - Described herein are novel pyrimidine-pyridine compounds, methods of inhibiting methionine aminopeptidase and treating disorders (or symptoms thereof) associated with methionine aminopeptidase, wherein a compound of the invention is administered to a subject. | 2011-05-26 |
20110124650 | STABLE CRYSTALLINE SALTS OF ANTIFOLATE COMPOUNDS - The present invention provides stable crystalline polymorphic forms of antifolate compounds, particularly (S)-2-{4-[2-(2,4-diamino-quinazolin-6-yl)-ethyl]-benzoylamino}-4-methylene-pentanedioic acid, dipotassium salt, and methods of preparation thereof The polymorphs may be in the form of hydrates. The invention further provides pharmaceutical compositions comprising the polymorphs and methods of treatment using the polymorphs. The polymorphs are useful in the treatment of multiple conditions, including abnormal cell proliferation, inflammatory diseases, asthma, and arthritis, and the polymorphs may be administered alone in or combination with on or more further active agents. | 2011-05-26 |
20110124651 | FLUORINE-CONTAINING ORGANOSULFUR COMPOUND AND PESTICIDAL COMPOSITION THEREOF - There is provided a fluorine-containing organosulfur compound having an excellent control effect on harmful arthropods, which is represented by the formula (I): wherein m represents 0 or 1; n represents 0, 1 or 2; A represents an optionally substituted 6-membered aromatic heterocyclic group; R | 2011-05-26 |
20110124652 | Chemical Compounds and Uses - The present invention relates to novel compounds that are useful in the treatment of metabolic disorders, particularly type II diabetes mellitus and related disorders, and also to the methods for the making and use of such compounds. | 2011-05-26 |
20110124653 | ARYL-SULPHONAMIDIC DIMERS AS METALLOPROTEASES INHIBITORS - The invention relates to dimeric aryl-sulphonamido compounds endowed with inhibitory activity against metalloproteases MMP, having formula (I) below (M)-L-(M′) (I), wherein M and M′, the same or different from each other, represent the residues of the metalloproteases inhibitors of formula (II), wherein R, R | 2011-05-26 |
20110124654 | DIAZACARBAZOLES AND METHODS OF USE - The invention relates to 1,5-diazacarbazole compounds of Formula (I), (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g) and (I-h) which are useful as kinase inhibitors, more specifically useful as checkpoint kinase 1 (chk1) inhibitors, thus useful as cancer therapeutics. The invention also relates to compositions, more specifically pharmaceutical compositions comprising these compounds and methods of using the same to treat various forms of cancer and hyperproliferative disorders, as well as methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions. | 2011-05-26 |
20110124655 | KMUP-1 CAPABLE OF TREATING HYPERTENSION - A cardiomyocyte hypertrophy inhibiting pharmaceutical composition is provided. The composition comprises an effective amount of a compound of 7-[2-[4-(2-chlorobenzene)piperazinyl]ethyl]-1,3-dimethylxanthine; and a pharmaceutically acceptable carrier. | 2011-05-26 |
20110124656 | Methods and Compositions for Treating Symptoms Associated with Post-Traumatic Stress Disorder using Cyclobenzaprine - The present invention relates to methods for the treatment or prevention of symptoms associated with post-traumatic stress disorder, and related pharmaceutical compositions. Of particular interest are pharmaceutical compositions comprising a very low dose of cyclobenzaprine, alone, or in combination with an alpha-1-adrenergic receptor antagonist, a beta-adrenergic antagonist, an anticonvulsant, a selective serotonin reuptake inhibitor or a serotonin-norepinephrine reuptake inhibitor. | 2011-05-26 |
20110124657 | METHOD FOR SCREENING OF 5HT7 RECEPTOR LIGANDS BASED ON A NEW PHARMACOPHORE MODEL AND A DESCRIPTOR'S PROFILE FILTER - The present invention relates to compounds having pharmacological activity towards the 5-HT | 2011-05-26 |
20110124658 | SUBSTITUTED OXINDOLE DERIVATIVES AND THEIR USE AS VASOPRESSIN RECEPTOR LIGANDS - The present invention relates to novel oxindole derivatives of the general formula (I) to medicaments comprising them and to their use for the prophylaxis and/or treatment of diseases vasopressin dependent. | 2011-05-26 |
20110124659 | CYCLOALKANE DERIVATIVE - The present invention relates to a novel cycloalkane derivative which has a useful psychotropic action with less side effect. | 2011-05-26 |
20110124660 | Novel Diazinylpyrazolyl Compounds - The present invention relates to diazinylpyrazolyl compounds of the formula (I) | 2011-05-26 |
20110124661 | OXAZOLOBENZIMIDAZOLE DERIVATIVES - The present invention is directed to oxazolobenzimidazole derivatives which are potentiators of metabotropic glutamate receptors, particularly the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved. | 2011-05-26 |
20110124662 | Substituted Carbamate Derivatives as Modulators of Corticotropin-Releasing Factor Receptor Activity - The disclosure provides compounds of formula (I), including their salts, as well as compositions and methods of using the compounds. The compounds are CRF receptor antagonists and may be useful for treating disorders associated with abnormal CRF levels or aberrant functioning of CRF receptors. | 2011-05-26 |
20110124663 | SUBSTITUTED DIOXOPIPERIDINES AND DIOXOPYRROLIDINES AS MGLUR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION - In one aspect, the invention relates to compounds having a general structure: | 2011-05-26 |
20110124664 | Polycationic Compounds And Uses Thereof - Aspects of the present invention relate to compounds and methods useful in modulating angiogenesis and methods of treating or preventing diseases associated with angiogenesis by administering a polycationic compound. The present invention relates to methods of use and compositions for inhibiting angiogenesis-mediated disorders in mammals including animals and humans. Additionally, this invention relates to the combined use of polycations with other anti-angiogenesis agents for the treatment of different angiogenesis-mediated disorders. Additionally, those polycationic compounds can be used with various anti-inflammatory and cytotoxic agents as well as with radio-therapeutic agents in cancer patients to prevent and treat tumor growth and metastasis. | 2011-05-26 |
20110124665 | Novel, Cyclically Substituted Furopyrimidine Derivatives and Use Thereof - The present application relates to novel, cyclically substituted furopyrimidine derivatives, methods for their production, their use for the treatment and/or prophylaxis of diseases and their use for the production of medicinal products for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular diseases. | 2011-05-26 |
20110124666 | 3,4-DIHYDROPYRIMIDINE TRPA1 ANTAGONISTS - The present invention is related to novel 3,4-dihydropyrimidine compounds of formula (I) having TRPA1 receptor antagonistic properties, pharmaceutical compositions comprising these compounds, chemical processes for preparing these compounds and their use in the treatment of diseases linked to the modulation of the TRPA1 receptors in animals, in particular humans. | 2011-05-26 |
20110124667 | METHODS FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME - Methods of treating irritable bowel syndrome (IBS) are disclosed. Assays and kits useful in the treatment of IBS are also disclosed. | 2011-05-26 |
20110124668 | NOVEL INDOLE DERIVATIVE HAVING, CARBAMOYL GROUP, UREIDO GROUP AND SUBSTITUTED OXY GROUP - The present invention relates to synthetic studies on novel indole derivatives having a carbamoyl group, a ureido group and a substituted oxy group or a salt thereof, and pharmaceutical actions of the derivatives. The compound and a salt thereof represented by the general formula (1) has an IKKβ inhibitory activity and is useful as a preventive and/or therapeutic agent for diseases considered to be associated with IKKβ. In the formula, R | 2011-05-26 |
20110124669 | Modulators of Cellular Adhesion - The present invention provides compounds having formula (I): | 2011-05-26 |
20110124670 | Use of Pyrimidylaminobenzamide Derivatives for the Treatment of Fibrosis - The invention relates to the use of a pyrimidylaminobenzamides of formula I | 2011-05-26 |
20110124671 | SPIROINDENES AND SPIROINDANES AS MODULATORS OF CHEMOKINE RECEPTORS - The present invention relates to a compound of the following formula: | 2011-05-26 |
20110124672 | Thienyl Compounds - Compounds of formula I: | 2011-05-26 |
20110124673 | 6-ALKENYL AND 6-PHENYLALKYL SUBSTITUTED 2-QUINOLINONES AND 2-QUINOXALINONES AS POLY(ADP-RIBOSE) POLYMERASE INHIBITORS - The present invention provides compounds of formula (I) and compounds of formula (VII-a) as well as pharmaceutical compositions comprising said compounds and their use as PARP inhibitors | 2011-05-26 |
20110124674 | 5/5-OR 5/6-MEMBERED CONDENSED RING CYCLOALKYLAMINE DERIVATIVE - Disclosed are a compound of a formula (I) and its pharmaceutically-acceptable salt: | 2011-05-26 |
20110124675 | THE HYDROSULFATE OF PRASUGREL, ITS PHARMACEUTICAL COMBINATION AND USE THEREOF - The present invention provides the prasugrel bisulfate of formula (II) and pharmaceutical composition and use thereof. Prasugrel bisulfate of the present invention has good stability, oral absorbability, metabolic activity and platelet aggregation inhibition effect, and low toxicity, and is therefore a promising anticoagulant for preventing or treating diseases associated with thrombosis or embolism. | 2011-05-26 |
20110124676 | BIARYL SUBSTITUTED AZABICYCLIC ALKANE DERIVATIVES - The invention relates to biaryl substituted azabicyclic alkane derivatives, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions. | 2011-05-26 |
20110124678 | TREATMENT WITH ALPHA 7-SELECTIVE LIGANDS - The present invention includes methods, uses, and selective α7 nAChR agonist compounds for treating or preventing metabolic disorders. | 2011-05-26 |
20110124679 | 2-SUBSTITUTED-p-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES - Methods of treating or suppressing oxidative stress diseases including mitochondrial diseases, impaired energy processing disorders, neurodegenerative diseases and diseases of aging are disclosed, as well as compounds useful in the methods of the invention, such as 2-substituted-p-quinone derivatives as disclosed herein. | 2011-05-26 |
20110124680 | NOVEL ANTHRANILAMIDE PYRIDINUREAS AS VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) RECEPTOR KINASE INHIBITORS - The invention relates to novel anthranilamide pyridinureas as VEGF receptor kinase inhibitors, their production and use as pharmaceutical agents for preventing or treating diseases that are triggered by persistent angiogenesis. | 2011-05-26 |
20110124681 | TOPICAL AND INJECTABLE FORMULATIONS COMPRISING LEUKOTRIENE RECEPTOR ANTAGONIST AND USES THEREOF - Methods of treating, preventing, reducing the occurrence of, or slowing progression of folliculitis, partial or full hair loss, thinning of the hair, changes in the texture of hair, graying or whitening (loss of pigmentation) of the hair, dermatological conditions, and other hair-related conditions, comprising administering topical and injectable formulations containing one or more leukotriene receptor antagonists. | 2011-05-26 |
20110124682 | PHARMACEUTICAL COMPOSITION COMPRISING REBAMIPIDE - An object of the present invention is to provide a pharmaceutical composition containing rebamipide, which is unnecessary to be re-dispersed, has an enough transparency, and exhibits neutral to weakly acidic pH not to injure the keratoconjunctiva of a patient suffering from dry eye. The present pharmaceutical composition comprises (1) rebamipide, (2) an amino sugar, and (3) an buffer agent, which has no inorganic cation. | 2011-05-26 |
20110124683 | Use of CRTH2 Antagonist Compounds - The invention relates to compounds of general formula (I): | 2011-05-26 |
20110124684 | AMINOPYRAZOLE TRIAZOLOTHIADIAZOLE INHIBITORS OF C-MET PROTIEN KINASE - The present invention relates to compounds of formula I, which is useful in the inhibition of c-Met protein kinase. The invention also provides pharmaceutically acceptable compositions comprising compounds of formula I and methods of using the compositions in the treatment of proliferative disorders. | 2011-05-26 |
20110124685 | Anesthetic Compounds - The invention provides novel phenolic ester local anesthetic compounds. The invention also provides pharmaceutical compositions that include such compounds as well as methods for making such compounds and compositions and methods for using such compounds and compositions to induce and/or maintain anesthesia and/or analgesia. | 2011-05-26 |
20110124686 | SULTAM DERIVATIVES - The present invention relates to compounds according to formula 1, | 2011-05-26 |
20110124687 | PHARMACEUTICAL COMPOSITION - The present invention provides a pharmaceutical composition or a solid preparation containing a stabilized pharmaceutically active ingredient and a stabilizing method thereof. | 2011-05-26 |
20110124688 | NICOTINE RECEPTOR AGONISTS IN STEM CELL AND PROGENITOR CELL RECRUITMENT - The present invention features methods for recruitment of bone marrow-derived stem cells (e.g., endothelial cell precursors, hematopoietic stem cells) by administration of nicotine or other nicotine receptor agonist. The methods of the invention can be used in, for example, treatment of conditions amenable to treatment by recruitment of bone marrow-derived stem cells (e.g., neutropenia). | 2011-05-26 |
20110124689 | PROCESS FOR PREPARING ATAZANAVIR BISULFATE AND NOVEL FORMS - A process is provided for preparing the HIV protease inhibitor atazanavir bisulfate wherein a solution of atazanavir free base is reacted with concentrated sulfuric acid in an amount to react with less than about 15% by weight of the free base, seeds of Form A crystals of atazanavir bisulfate are added to the reaction mixture, and as crystals of the bisulfate form, additional concentrated sulfuric acid is added in multiple stages at increasing rates according to a cubic equation, to effect formation of Form A crystals of atazanavir bisulfate. | 2011-05-26 |
20110124690 | COMPOSITIONS AND METHODS FOR TREATING CANCER OR A NEUROTROPHIC DISORDER - The present invention relates to compositions comprising an effective amount of a Panaxytriol Compound and a tubulin-binding drug, methods for treating or preventing cancer or a neurotrophic disorder comprising administering to a subject in need thereof an effective amount of a Panaxytriol Compound and a tubulin-binding drug, and methods for making a Panaxytriol Compound. | 2011-05-26 |
20110124691 | Organic Compounds - Pharmaceutical formulations comprising an epothilone in the form of an infusion concentrate or a lyophilised composition, and methods of administration of an epothilone in suitable form for parenteral administration. | 2011-05-26 |
20110124692 | CRYSTALLINE FORMS OF THIAZOLIDINEDIONE COMPOUND AND ITS MANUFACTURING METHOD - Thiazolidinedione compound crystalline forms useful as a bulk material for the manufacture of a peroxisome proliferator-activated receptor (PPAR) γ activator or an anticancer pharmaceutical composition are provided, which are hydrate crystalline forms of 5-(4-{[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1-H-benzimi dazol-2-yl]methoxy}benzyl)-1,3-thiazolidine-2,4-dione represented by Formula (I) below and of its dihydrochloride. | 2011-05-26 |
20110124693 | 5-PHENYL-4-METHYL-THIAZOL-2-YL-AMINE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL 3 KINASE ENZYMES (PI3) FOR THE TREATMENT OF INFLAMMATORY DISEASES - Compounds of Formula I: | 2011-05-26 |
20110124694 | BIOAVAILABLE COMPOSITIONS OF METAXALONE AND PROCESSES FOR PRODUCING THE SAME - Pharmaceutical compositions comprising metaxalone which demonstrate improved dissolution and bioavailability characteristics compared to the commercially available product, and methods of producing them are provided. In a preferred embodiment, a dosage form comprising metaxalone and at least one inactive powder excipient is bioequivalent to its commercially available counterpart (Skelaxin® 400-mg tablets) after oral administration to fasting or non-fasting human subjects, while at the same time displaying faster drug dissolution rates than the Skelaxin® tablets as demonstrated from three different dissolution tests. In another preferred embodiment, a dosage form comprising metaxalone, at least one inactive powder excipient and a nonvolatile liquid is significantly more bioavailable than the commercially available Skelaxin® 400-mg tablets after oral administration to fasting human subjects. | 2011-05-26 |
20110124695 | Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors - The present invention provides a compound of formula I: | 2011-05-26 |
20110124696 | Sulfone Compounds Which Modulate The CB2 Receptor - Compounds which modulate the CB2 receptor are disclosed. Compounds according to the invention bind to and are agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally useful for treating pain. | 2011-05-26 |
20110124697 | COMPOSITIONS BASED ON AMINOACIDS, SUITABLE FOR THE TREATMENT OF HEART FAILURE - Compositions based on amino acids are described, in particular for oral or parenteral use, suitable for treating heart insufficiency. The compositions according to the invention comprise up to 75% of the branched chain amino acids leucine, isoleucine and valine, as active ingredients. Preferably, the compositions also comprise, as further active ingredients, up to 50% of theronine and lysine. Other essential amino acids are preferably also provided (in particular methionine, phenylalanine, histidine, triphtophan) as well as non essential amino acids (in particular tyrosine and/or cyst(e)ine—i.e., cystine and cyst(e)ine). Other amino acids can be added, provided that their sum is in a percentage being lower than 20% with respect to the other active ingredients, and less than 10% for each single amino acid. | 2011-05-26 |
20110124698 | Iodopyrazolyl Carboxanilides - This invention relates to novel intermediates used in the preparation of iodopyrazolylcarboxanilides of the formula (I) | 2011-05-26 |
20110124699 | METHOD FOR TREATING NERVOUS SYSTEM DISORDERS AND CONDITIONS - The present invention is directed to racemic 1-(3,4-dichlorophenyI)-3-azabicyclo[3.1.0]hexane, (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1 .0]hexane, racemic 1-(4-methylphenyl)-3-azabicyclo[3.1.0]hexane, and (+)-1-(4-methylphenyl)-3-azabicyclo[3.1.0]hexane, and methods of their use for treating certain nervous system disorders and conditions, including, inter alia, vasomotor symptoms (VMS) and chronic pain. | 2011-05-26 |
20110124700 | SYSTEMS AND METHODS OF CANCER STAGING AND TREATMENT - Methods of assessing the sensitivity of a cancer cell to a tyrosine kinase inhibitor are disclosed. Such methods include assessing the expression of miR-497 and correlating reduced expression with sensitivity to the tyrosine kinase inhibitor. Also disclosed are methods of assessing the sensitivity of a cell to a tyrosine kinase inhibitor that includes assessing the expression of FGF1, HOXC10, and/or LHFP. Additionally disclosed are methods of treating patients with tyrosine kinase inhibitors such as sunitinib based on results obtained from the disclosed methods and kits that facilitate the methods. | 2011-05-26 |
20110124701 | USE OF HDAC INHIBITORS FOR THE TREATMENT OF LYMPHOMAS - The present invention relates to the use of an HDAC inhibitor, especially an HDAC inhibitor of formula (I): | 2011-05-26 |
20110124702 | Nanosuspension of a Poorly Soluble Drug via Microfluidization Process - Provided are compositions and methods for preparation and administration of an oral nanosuspension of a poorly soluble drug with improved bioavailability. The method is optimized through microfluidization process with water soluble polymeric excipients in the absence of surfactants. | 2011-05-26 |
20110124703 | MOLECULES COMPRISING A BIS(HETEROARYL)MALEIMIDE BACKBONE, AND USE THEREOF IN THE INHIBITION OF DDE/DDD ENZYMES - The invention concerns molecules with a bis-(heteroaryl)maleimide structure and having inhibiting characteristics with respect to enzymes with a catalytic pocket comprising the invariant amino acids D, D and E or D, D and D, such as transposases, RAG recombinases or retroviral integrases. The invention also concerns the use of said molecules for in vitro, ex vivo or in vivo inhibition of transposases, RAG recombinases and retroviral integrases such as HIV integrase, as well as the use of said molecules in the treatment of diseases associated with these enzymes in an animal or human host, in particular in the treatment of AIDS. | 2011-05-26 |
20110124704 | DEUTERIUM-ENRICHED ATORVASTATIN - The present application describes deuterium-enriched atorvastatin, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2011-05-26 |